Changjin Hong

Changjin Hong

Auto-generated profile, based on publicly available information

Changjin Hong

Department of Artificial Intelligence and Informatics, Mayo Clinic, Jacksonville, Florida

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2022 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
SPSunho Park
Sunho Park
JKJohn Karalis
John Karalis
CHChangjin Hong
Changjin Hong
JCJean R. Clemenceau
Jean R. Clemenceau
MPMatthew R. Porembka
Matthew R. Porembka
THTae Hyun Hwang
Tae Hyun Hwang
Purpose: We sought to identify biomarkers that predict overall survival (OS) and response to immune checkpoint inhibitors (ICI) for patients with gastric cancer. Experimental Design: This was a retrospective study of multiple independent cohorts of patients with gastric cancer. The association between tumor ACTA2 expression and OS and ICI response were determined in patients whose tumors were analyzed with bulk mRNA sequencing. Single-cell RNA sequencing (scRNA-seq) and digital spatial profiling data were used to compare tumors from patients with gastric cancer who did and did not respond to ICI. Results: Increasing tumor ACTA2 expression was independently associated with worse OS in a 567-patient discovery cohort [HR, 1.28 per unit increase; 95% confidence interval (CI), 1.02–1.62]. This finding was validated in three independent cohorts (n = 974; HR, 1.52 per unit increase; 95% CI, 1.34–1.73). Of the 108 patients treated with ICI, 56% of patients with low ACTA2 expression responded to ICI versus 25% of patients with high ACTA2 expression (P = 0.004). In an analysis of a publicly available scRNA-seq dataset of 5 microsatellite instability-high patients treated with ICI, the patient who responded to ICI had lower tumor stromal ACTA2 expression than the 4 nonresponders. Digital spatial profiling of tumor samples from 4 ICI responders and 5 ICI nonresponders revealed that responders may have lower ACTA2 expression in α-SMA–positive cancer-associated fibroblasts (CAF) than nonresponders (median: 5.00 vs. 5.50). Conclusions: ACTA2 expression is associated with survival and ICI response in patients with gastric cancer. ACTA2 expression in CAFs, but not in other cellular compartments, appears to be associated with ICI response.

25 April 2005
Verified
Conference Paper
Closed access
ALA.E. Lawabni
A.E. Lawabni
CHChangjin Hong
Changjin Hong
DDD.H.C. Du
D.H.C. Du
ATA.H. Tewfik
A.H. Tewfik
To date, the systems approach to science, which emphasizes the connections among phenomena studied at different scales and by different disciplines, is causing dramatic changes in how scientific results are communicated. These changes drive a shift on how to propagate data with certain properties so that it can be used intelligently by others. In this work we elaborate on three major factors governing the propagation module of data provenance. The proposed propagation module provides an efficient solution for many critical problems in the management and provenance of scientific data. Unlike previous work, our work aims at realizing data provenance from models to storage. The natural representation of data as objects and its utility for capturing provenance has led us to consider a new storage architecture based on the object-based storage (OSD) technology. An outline of this framework is discussed.

1 April 2023
Verified
Other
Open access
SPSunho Park
Sunho Park
JKJohn Karalis
John Karalis
CHChangjin Hong
Changjin Hong
JCJean R. Clemenceau
Jean R. Clemenceau
MPMatthew R. Porembka
Matthew R. Porembka
THTae Hyun Hwang
Tae Hyun Hwang
Purpose:We sought to identify biomarkers that predict overall survival (OS) and response to immune checkpoint inhibitors (ICI) for patients with gastric cancer.Experimental Design:This was a retrospective study of multiple independent cohorts of patients with gastric cancer. The association between tumor ACTA2 expression and OS and ICI response were determined in patients whose tumors were analyzed with bulk mRNA sequencing. Single-cell RNA sequencing (scRNA-seq) and digital spatial profiling data were used to compare tumors from patients with gastric cancer who did and did not respond to ICI.Results:Increasing tumor ACTA2 expression was independently associated with worse OS in a 567-patient discovery cohort [HR, 1.28 per unit increase; 95% confidence interval (CI), 1.02–1.62]. This finding was validated in three independent cohorts (n = 974; HR, 1.52 per unit increase; 95% CI, 1.34–1.73). Of the 108 patients treated with ICI, 56% of patients with low ACTA2 expression responded to ICI versus 25% of patients with high ACTA2 expression (P = 0.004). In an analysis of a publicly available scRNA-seq dataset of 5 microsatellite instability-high patients treated with ICI, the patient who responded to ICI had lower tumor stromal ACTA2 expression than the 4 nonresponders. Digital spatial profiling of tumor samples from 4 ICI responders and 5 ICI nonresponders revealed that responders may have lower ACTA2 expression in α-SMA–positive cancer-associated fibroblasts (CAF) than nonresponders (median: 5.00 vs. 5.50).Conclusions:ACTA2 expression is associated with survival and ICI response in patients with gastric cancer. ACTA2 expression in CAFs, but not in other cellular compartments, appears to be associated with ICI response.

1 April 2023
Verified
Other
Open access
SPSunho Park
Sunho Park
JKJohn Karalis
John Karalis
CHChangjin Hong
Changjin Hong
JCJean R. Clemenceau
Jean R. Clemenceau
MPMatthew R. Porembka
Matthew R. Porembka
THTae Hyun Hwang
Tae Hyun Hwang
Supplementary Figure 1. ACTA2 expression was elevated in the molecular subtype with the worst prognosis (Group 4). Supplementary Figure 2. ACTA2 expression stratified by microsatellite stability status in the pooled cohort. Supplementary Figure 3. Alternatively tested thresholds to stratify patients into ACTA2-High and ACTA2-Low groups.Supplementary Figure 4. ACTA2 expression stratified by microsatellite stability status in the immune checkpoint inhibitor cohort.

1 April 2023
Verified
Other
Open access
SPSunho Park
Sunho Park
JKJohn Karalis
John Karalis
CHChangjin Hong
Changjin Hong
JCJean R. Clemenceau
Jean R. Clemenceau
MPMatthew R. Porembka
Matthew R. Porembka
THTae Hyun Hwang
Tae Hyun Hwang
Supplementary Table 1. Univariable associations of the multivariable Cox proportional hazards model in the Yonsei cohort.Supplementary Table 2. Clinical characteristics of patients in the pooled validation cohort.Supplementary Table 3. Univariable associations of the multivariable Cox proportional hazards model of the pooled validation cohort.Supplementary Table 4. Univariable Cox proportional hazards regression of the association of individual genes of the 32-gene signature and their association with overall survival in the Yonsei cohort.Supplementary Table 5. Univariable Cox proportional hazards regression of the association of individual genes of the 32-gene signature and their association with overall survival in the pooled cohort.Supplementary Table 6. Multivariable analysis of the pooled cohort including microsatellite stability status.Supplementary Table 7. Multivariable analysis of the association of ACTA2 expression with recurrence-free survival in the pooled cohort.Supplementary Table 8. Clinical characteristics of patients treated with immune checkpoint inhibitors.Supplementary Table 9. ACTA2 expression in cells analyzed by single nuclear RNA sequencing cohort.Supplementary Table 10. Characteristics of patients analzyed by digital spatial transcriptomics.

27 April 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
ZJZachary Jackson
Zachary Jackson
CHChangjin Hong
Changjin Hong
RSRobert Schauner
Robert Schauner
BDBoro Dropulic
Boro Dropulic
PCpaolo caimi
paolo caimi
DWDavid N. Wald
David N. Wald
Chimeric antigen receptor T cell (CAR-T cell) therapy is known to produce durable remissions in the treatment of CD19 + relapsed/refractory B cell malignancies. Nonetheless, a significant portion of patients receiving the therapy experience poor outcomes in the acute response for unknown reasons. Given the decreased expansion and persistence of CD8 CAR-T cells in poor outcome groups, this failure may be attributed to CAR-T cell dysfunction. However, a comparison of the post-infusion transcriptional profiles and phenotypes between CAR-T cells of poor and favorable response groups has not been performed. Here, we employed single cell RNA sequencing and protein surface marker profiling of serial CAR-T cell blood samples from patients with CD19 + relapsed/refractory non-Hodgkin’s lymphoma (NHL) to reveal CAR-T cell evolution, identify biomarkers of response, and test for evidence of exhaustion in CAR-T cells of poor responders. At the transcriptional and protein levels, we note the evolution of a majority of CAR-T cells toward a non-proliferative and highly-differentiated state. In poor outcome patients, we observed a more marked enrichment of an exhaustion profile as compared to favorable outcome patients. Lastly, we identified the checkpoint receptor TIGIT (T cell immunoreceptor with Ig and ITIM domains) as a novel prognostic biomarker and potential driver of CAR-T cell exhaustion. Altogether, we provide evidence of CAR-T cell dysfunction marked by TIGIT expression driving poor response in NHL patients.